Patriot Financial Group Insurance Agency’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-3,308
Closed -$353K 517
2024
Q2
$353K Sell
3,308
-2,413
-42% -$265K 0.05% 328
2024
Q1
$689K Buy
5,721
+114
+2% +$14K 0.11% 208
2023
Q4
$690K Buy
5,607
+294
+6% +$36.7K 0.13% 188
2023
Q3
$688K Sell
5,313
-3,188
-38% -$425K 0.14% 178
2023
Q2
$1.05M Sell
8,501
-708
-8% -$95.3K 0.2% 123
2023
Q1
$1.35M Buy
9,209
+2,218
+32% +$328K 0.27% 82
2022
Q4
$1.11M Sell
6,991
-191
-3% -$28K 0.15% 92
2022
Q3
$957K Buy
+7,182
New +$1.09M 0.23% 104
2020
Q4
Sell
-2
Closed 1921
2020
Q3
$0 Hold
2
﹤0.01% 1757
2020
Q2
$0 Hold
2
﹤0.01% 1750
2020
Q1
$0 Hold
2
﹤0.01% 1646
2019
Q4
$0 Hold
2
﹤0.01% 1379
2019
Q3
$0 Hold
2
﹤0.01% 1388
2019
Q2
$1K Hold
2
﹤0.01% 1258
2019
Q1
$0 Hold
2
﹤0.01% 1264
2018
Q4
$0 Buy
+2
New +$297 ﹤0.01% 1055

Other funds holding JAZZ

Patriot Financial Group Insurance Agency's JAZZ Position: Q3 2024 in Review

Patriot Financial Group Insurance Agency sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2024, closing a stake of 3,308 shares — an estimated $353K sold.

Patriot Financial Group Insurance Agency first reported a position in JAZZ in Q4 2018 and held it in 16 quarters. The position peaked at $1.35M in Q1 2023. 477 funds tracked by Wall St. Rank hold JAZZ as of Q3 2024.

  • Patriot Financial Group Insurance Agency reported no remaining Jazz Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Patriot Financial Group Insurance Agency sold 3,308 Jazz Pharmaceuticals shares in Q3 2024, an estimated $353K.
  • Patriot Financial Group Insurance Agency first reported a position in Jazz Pharmaceuticals in Q4 2018 and held it in 16 quarters.
  • Patriot Financial Group Insurance Agency's Jazz Pharmaceuticals position peaked at $1.35M in Q1 2023.
  • 477 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2024.

Based on Patriot Financial Group Insurance Agency's 13F filing for Q3 2024, filed 24 Oct 2024.